Jefferies Starts SXC Health Solutions (SXCI) at Buy
Get Alerts SXCI Hot Sheet
Price: $93.02 --0%
Rating Summary:
11 Buy, 6 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
11 Buy, 6 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Before the open, Jefferies initiated coverage on SXC Health Solutions (NASDAQ: SXCI) with a Buy rating and $71 price target.
The firm said, "While the stock has had 500% run-up in the last two years, we believe SXC remains attractive given the company's strong contracting momentum, growing scale and operating leverage, solid business model that is well-positioned to take advantage of the PBM sector's near- and long-term fundamentals, and potential upside from likely capital deployment (i.e., acquisitions)."
For more ratings news on SXC Health Solutions click here and for the rating history of SXC Health Solutions click here.
Shares of SXC Health Solutions closed at $58.88 yesterday.
The firm said, "While the stock has had 500% run-up in the last two years, we believe SXC remains attractive given the company's strong contracting momentum, growing scale and operating leverage, solid business model that is well-positioned to take advantage of the PBM sector's near- and long-term fundamentals, and potential upside from likely capital deployment (i.e., acquisitions)."
For more ratings news on SXC Health Solutions click here and for the rating history of SXC Health Solutions click here.
Shares of SXC Health Solutions closed at $58.88 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Raymond James Starts SpyGlass Pharma (SGP) at Outperform
- RBC Capital Starts Krystal Biotech (KRYS) at Outperform
- BofA Securities Resumes American Eagle Outfitters (AEO) at Underperform
Create E-mail Alert Related Categories
Hot New Coverage, New CoverageRelated Entities
Jefferies & CoSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share